摘要
目的探讨聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙肝的临床效果。方法方便选取该院2018年6月—2019年6月收治的130例慢性乙肝患者,按照入院顺序随机编号后分成对照组与观察组,对照组患者接受聚乙二醇干扰素α-2a治疗,观察组患者在对照组用药基础上辅助恩替卡韦治疗,两组患者接受相同的治疗时间,通过对比两组患者临床治疗效率以及丙氨酸转氨酶水平(ALT)、HBeAg转阴率以及HBV-DNA转阴率,观察两组患者的临床效果。结果观察组患者的临床治疗有效率为93.85%;对照组患者的临床治疗有效率为75.38%,较观察组低,差异有统计学意义(χ2=6.27,P<0.05);治疗后观察患者ALT水平为(157.47±14.52)U/L低于对照组(211.42±14.67)U/L(t=14.329,P<0.05);观察组的HBV-DNA转阴率以及HBeAg转阴率分别为87.69%,83.08%,均显著高于对照组43.08%,47.69%,两组患者的各项数据对比,差异有统计学意义(χ2=5.44、6.72,P<0.05)。结论聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙肝的临床效果良好,有效改善患者的临床病症,同时显著提高患者的肝功能以及临床治疗有效率。
Objective To investigate the clinical effect of pegylated interferonα-2a combined with entecavir in the treatment of chronic hepatitis B.Methods 130 patients with chronic hepatitis B admitted to the hospital from June 2018 to June 2019 were convenient randomly divided into control group and observation group.The patients in control group were treated with pegylated interferonα-2a.The patients in observation group were treated with entecavir on the basis of medication in control group.The patients in two groups received the same treatment.By comparing the clinical treatment efficiency,alanine aminotransferase level(ALT),negative rate of HBeAg and negative rate of HBV-DNA between the two groups,the clinical effect of the two groups was observed.Results The clinical effective rate of the observation group was 93.85%;the clinical effective rate of the control group was 75.38%,lower than that of the observation group,and the different had statistical significance(χ2=6.27,P<0.05);after treatment,the ALT level of the patients was(157.47±14.52)U/L lower than the control group(211.42±14.67)U/L(t=14.329,P<0.05);the HBV-DNA negative rate of the observation group and the HBeAg negative rates were 87.69%and 83.08%,which were significantly higher than the control group's 43.08%and 47.69%.The difference of data comparison between the two groups of patients was.was statistically significant(χ2=5.44,6.72,P<0.05).Conclusion PEG interferonα-2a combined with entecavir has a good clinical effect in treating chronic hepatitis B.It can effectively improve the clinical symptoms and liver function of patients,as well as the efficiency of clinical treatment.
作者
田旭杰
穆泉汝
杨俊晓
臧玮
TIAN Xu-jie;MU Quan-ru;YANG Jun-xiao;ZANG Wei(Department of Hepatology,Weihai Thoracic Hospital,Weihai,Shandong Province,264200 China)
出处
《中外医疗》
2020年第9期23-25,共3页
China & Foreign Medical Treatment
关键词
二醇干扰素
慢性乙肝
恩替卡韦
Interferon diol
Chronic hepatitis B
Entecavir
